Latest Content

A study found that the investigational antiviral mosnodenvir reduced dengue virus infection RNA levels and symptoms in a controlled setting, supporting its potential as a prophylactic option.

Phase 3 ISLEND-1 and ISLEND-2 trials showed once-weekly oral islatravir/lenacapavir was noninferior to daily BIKTARVY and standard of care ART in maintaining virologic suppression at Week 48, with no new safety concerns identified.

A large platform trial evaluates diverse medications to relieve fatigue persisting post-acute COVID-19.

Although there has been conflicting public information around whether the source of the outbreak has been determined, Catherine O’Neal, MD, offers insights on key symptoms that warrant medical evaluation, what medical treatment may consist of for those being seen in an outpatient setting or those who are hospitalized, and considerations around eating produce.

The stark contrast between the rapid global response to the Andes virus exposure on a cruise ship and the slower, under-resourced response to the Bundibugyo Ebola outbreak in Central Africa highlights how global health inequities—and the disproportionate burden placed on women caregivers—shape infectious disease outcomes as much as the pathogens themselves.

The FDA has accepted Shionogi's supplemental New Drug Application seeking to expand the indication for cefiderocol (Fetroja) to pediatric patients with hospital-acquired and ventilator-associated bacterial pneumonia and complicated urinary tract infections caused by susceptible Gram-negative bacteria, with a regulatory decision expected in February 2027.

A multistate cyclosporiasis outbreak has sickened thousands of people across five states, prompting federal investigators to advise consumers not to eat shredded iceberg lettuce served at affected Taco Bell locations.

From the early days with no treatment, to AZT providing a lifeline, to today’s generation of antiretroviral therapies (ART), Perry N. Halkitis, PhD, MS, MPH, reminds people of how they have transformed the lives of people with HIV.

Kartik Cherabuddi, MD, FACP, FIDSA, provides insights on these aspects of the parasitic infection.

Island Pharmaceuticals is leveraging the WHO's MEURI framework alongside the FDA Animal Rule pathway to evaluate investigational antiviral, galidesivir, during Africa's Bundibugyo Ebola outbreak while advancing regulatory development for a potential broad-spectrum filovirus therapy.

As of July 15, Michigan has reported 3,762 confirmed cases and investigators are still trying to locate the source of the infections.

This week, read about how laboratory antimicrobial susceptibility results may not predict clinical outcomes, watch a clinician discuss the DOTS and PETERPEN trials, the FDA has granted Priority Review to expand dolutegravir use to newborns with HIV, and more.

New research from Rutgers University suggests that bacterial responses to antibiotics vary significantly under nutrient-limited conditions, highlighting potential limitations of standard laboratory susceptibility testing and offering new insights into why some laboratory findings fail to predict clinical outcomes.